TY - JOUR
T1 - Cohort profile
T2 - Study on Zika virus infection in Brazil (ZIKABRA study)
AU - ZIKABRA Study Team
AU - Calvet, Guilherme Amaral
AU - Kara, Edna Oliveira
AU - Landoulsi, Sihem
AU - Habib, Ndema
AU - Boˆtto-Menezes, Camila Helena Aguiar
AU - De Franca, Rafael Freitas Oliveira
AU - Neto, Armando Menezes
AU - Castilho, Marcia Da Costa
AU - Fernandes, Tatiana Jorge
AU - Pereira, Gerson Fernando
AU - Giozza, Silvana Pereira
AU - Bermu´dez, Ximena Pamela Dı´az
AU - Modjarrad, Kayvon
AU - Lima, Noemia
AU - Brasil, Patrı´cia
AU - de Lacerda, Marcus Vinicius Guimarães
AU - de Filippis, Ana Maria Bispo
AU - Broutet, Nathalie Jeanne Nicole
AU - Abreu, Andre´ Luiz De
AU - Brito, Carlos Alexandre Antunes
AU - Lima, Morganna Costa
AU - de Mello, Maeve Brito
AU - Meurant, Robyn
AU - Pimenta, Cristina
AU - Storme, Casey
AU - Stro¨her, Ute
AU - Thorson, Anna
AU - Trautman, Lydie
N1 - Publisher Copyright:
© 2021 Public Library of Science. All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Zika virus (ZIKV) has been detected in blood, urine, semen, cerebral spinal fluid, saliva, amniotic fluid, and breast milk. In most ZIKV infected individuals, the virus is detected in the blood to one week after the onset of symptoms and has been found to persist longer in urine and semen. To better understand virus dynamics, a prospective cohort study was conducted in Brazil to assess the presence and duration of ZIKV and related markers (viral RNA, antibodies, T cell response, and innate immunity) in blood, semen, saliva, urine, vaginal secretions/menstrual blood, rectal swab and sweat. The objective of the current manuscript is to describe the cohort, including an overview of the collected data and a description of the baseline characteristics of the participants. Men and women ≥ 18 years with acute illness and their symptomatic and asymptomatic household contacts with positive reverse transcriptase-polymerase chain reaction test for ZIKV in blood and/or urine were included. All participants were followed up for 12 months. From July 2017 to June 2019, a total of 786 participants (284 men, 502 women) were screened. Of these, 260 (33.1%) were enrolled in the study; index cases: 64 men (24.6%), 162 (62.3%) women; household contacts: 12 men (4.6%), 22 (8.5%) women. There was a statistically significant difference in age and sex between enrolled and not enrolled participants (p<0.005). Baseline sociodemographic and medical data were collected at enrollment from all participants. The median and interquartile range (IQR) age was 35 (IQR; 25.3, 43) for men and 36.5 years (IQR; 28, 47) for women. Following rash, which was one of the inclusion criteria for index cases, the most reported symptoms in the enrollment visit since the onset of the disease were fever, itching, arthralgia with or without edema, non-purulent conjunctivitis, headache, and myalgia. Ten hospitalizations were reported by eight patients (two patients were hospitalized twice) during follow up, after a median of 108 days following symptom onset (range 7 to 266 days) and with a median of 1.5 days (range 1 to 20 days) of hospital stay. A total of 4,137 visits were performed, 223 (85.8%) participants have attended all visits and 37 (14.2%) patients were discontinued.
AB - Zika virus (ZIKV) has been detected in blood, urine, semen, cerebral spinal fluid, saliva, amniotic fluid, and breast milk. In most ZIKV infected individuals, the virus is detected in the blood to one week after the onset of symptoms and has been found to persist longer in urine and semen. To better understand virus dynamics, a prospective cohort study was conducted in Brazil to assess the presence and duration of ZIKV and related markers (viral RNA, antibodies, T cell response, and innate immunity) in blood, semen, saliva, urine, vaginal secretions/menstrual blood, rectal swab and sweat. The objective of the current manuscript is to describe the cohort, including an overview of the collected data and a description of the baseline characteristics of the participants. Men and women ≥ 18 years with acute illness and their symptomatic and asymptomatic household contacts with positive reverse transcriptase-polymerase chain reaction test for ZIKV in blood and/or urine were included. All participants were followed up for 12 months. From July 2017 to June 2019, a total of 786 participants (284 men, 502 women) were screened. Of these, 260 (33.1%) were enrolled in the study; index cases: 64 men (24.6%), 162 (62.3%) women; household contacts: 12 men (4.6%), 22 (8.5%) women. There was a statistically significant difference in age and sex between enrolled and not enrolled participants (p<0.005). Baseline sociodemographic and medical data were collected at enrollment from all participants. The median and interquartile range (IQR) age was 35 (IQR; 25.3, 43) for men and 36.5 years (IQR; 28, 47) for women. Following rash, which was one of the inclusion criteria for index cases, the most reported symptoms in the enrollment visit since the onset of the disease were fever, itching, arthralgia with or without edema, non-purulent conjunctivitis, headache, and myalgia. Ten hospitalizations were reported by eight patients (two patients were hospitalized twice) during follow up, after a median of 108 days following symptom onset (range 7 to 266 days) and with a median of 1.5 days (range 1 to 20 days) of hospital stay. A total of 4,137 visits were performed, 223 (85.8%) participants have attended all visits and 37 (14.2%) patients were discontinued.
UR - http://www.scopus.com/inward/record.url?scp=85099412485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099412485&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0244981
DO - 10.1371/journal.pone.0244981
M3 - Article
C2 - 33400705
AN - SCOPUS:85099412485
SN - 1932-6203
VL - 16
JO - PloS one
JF - PloS one
IS - 1 January
M1 - e0244981
ER -